|1.||Welch, Willard M: 1 article (01/2003)|
|2.||Buchan, Alistair M: 1 article (01/2003)|
|3.||Chenard, Bertrand L: 1 article (01/2003)|
|4.||Menniti, Frank S: 1 article (01/2003)|
|5.||Critchett, Donald J: 1 article (01/2003)|
|6.||Guanowsky, Victor: 1 article (01/2003)|
|7.||Ganong, Alan H: 1 article (01/2003)|
|8.||Seymour, Patricia A: 1 article (01/2003)|
01/01/2003 - "However, at comparable doses, CP-465,022 failed to prevent CA1 neuron loss after brief global ischemia or to reduce infarct volume after temporary middle cerebral artery occlusion. "
01/01/2003 - "Given the high selectivity of CP-465,022 for AMPA over kainate and N-methyl-D-aspartate subtypes of glutamate receptors, the lack of neuroprotective efficacy of the compound calls into question the neuroprotective efficacy of AMPA receptor inhibition after ischemia."
|2.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/01/2003 - "CP-465,022 potently and efficaciously inhibited AMPA receptor-mediated hippocampal synaptic transmission and the induction of seizures. "
01/01/2003 - "To demonstrate that CP-465,022 gains access to the brain, the effects of systemic administration of CP-465,022 were investigated on AMPA receptor-mediated electrophysiological responses in hippocampus and on chemically induced seizures in rats. "
|1.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|2.||AMPA Receptors (AMPA Receptor)
|3.||Glutamate Receptors (Glutamate Receptor)
|5.||Kainic Acid (Kainate)